Rumin8

Rumin8 is an Australian company focused on addressing climate change by reducing methane emissions from livestock. Founded in 2021, the company leverages a pharmaceutical approach to synthesize and stabilize bioactive compounds found in nature, specifically Tribromomethane (TBM) derived from red seaweed. This technology allows the production of feed supplements that are both cost-effective and scalable, aimed at significantly cutting the methane produced by enteric fermentation.

In November 2022, the company expanded its operations to the US by opening an office in Northern California. Following this, in January 2024, Rumin8 opened its first demonstration plant, allowing the company to produce thousands of doses a day (at full capacity) in support of its large-scale trials. In July 2024, the company received its first regulatory approval from the New Zealand Agricultural Compounds and Veterinary Medicines (ACVM).

Key customers and partnerships

The company’s research partners include educational institutions and research organizations like the University of Melbourne, UC Davis, CSIRO, ILVO, and AgResearch.

Funding and financials

In its latest funding round in January 2023, Rumin8 raised USD 12 million in its Phase II seed funding round. Breakthrough Energy Ventures led this investment round, with participation from Harvest Road Group, Aware Super Sentient WA Growth Fund, and Prelude Ventures. The funding was earmarked for expediting the commercialization process, conducting commercial trials, brand development efforts, and establishing a pilot manufacturing plant.